{"id":600,"date":"2013-11-27T20:23:03","date_gmt":"2013-11-27T20:23:03","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=600"},"modified":"2026-02-25T19:56:18","modified_gmt":"2026-02-25T19:56:18","slug":"breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/","title":{"rendered":"Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations (Contributed by Dr Matti A Rookus)"},"content":{"rendered":"<p><em>BRCA1<\/em> and <em>BRCA2<\/em> mutation carriers have increased risks of breast and ovarian cancer. In this Dutch study the authors examined these risks and their variation. We found that the average risks of breast and ovarian cancer by age 70 were 45% and 31%, respectively, for <em>BRCA1<\/em> and 27% and 6%, respectively, for <em>BRCA2<\/em> mutation carriers. Among <em>BRCA1<\/em> carriers the relatively low average risk estimates result from the lower risks in older generations and the lower risks in families with a moderate family history. Founder mutations also played a role. For <em>BRCA2<\/em> we did not find such explanations. (<a href=\"http:\/\/jmg.bmj.com\/content\/early\/2013\/11\/27\/jmedgenet-2013-101974\">http:\/\/jmg.bmj.com\/content\/early\/2013\/11\/27\/jmedgenet-2013-101974<\/a> )<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BRCA1 and BRCA2 mutation carriers have increased risks of breast and ovarian cancer. In this Dutch study the authors examined these risks and their variation. We found that the average risks of breast and ovarian cancer by age 70 were 45% and 31%, respectively, for BRCA1 and 27% and 6%, respectively, for BRCA2 mutation carriers. [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-600","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations (Contributed by Dr Matti A Rookus) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations (Contributed by Dr Matti A Rookus) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"BRCA1 and BRCA2 mutation carriers have increased risks of breast and ovarian cancer. In this Dutch study the authors examined these risks and their variation. We found that the average risks of breast and ovarian cancer by age 70 were 45% and 31%, respectively, for BRCA1 and 27% and 6%, respectively, for BRCA2 mutation carriers. [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2013-11-27T20:23:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-25T19:56:18+00:00\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/11\\\/27\\\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/11\\\/27\\\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations (Contributed by Dr Matti A Rookus)\",\"datePublished\":\"2013-11-27T20:23:03+00:00\",\"dateModified\":\"2026-02-25T19:56:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/11\\\/27\\\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\\\/\"},\"wordCount\":130,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/11\\\/27\\\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/11\\\/27\\\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/11\\\/27\\\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\\\/\",\"name\":\"Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations (Contributed by Dr Matti A Rookus) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"datePublished\":\"2013-11-27T20:23:03+00:00\",\"dateModified\":\"2026-02-25T19:56:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/11\\\/27\\\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/11\\\/27\\\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2013\\\/11\\\/27\\\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations (Contributed by Dr Matti A Rookus)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations (Contributed by Dr Matti A Rookus) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/","og_locale":"en_US","og_type":"article","og_title":"Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations (Contributed by Dr Matti A Rookus) - JMG Contact blog","og_description":"BRCA1 and BRCA2 mutation carriers have increased risks of breast and ovarian cancer. In this Dutch study the authors examined these risks and their variation. We found that the average risks of breast and ovarian cancer by age 70 were 45% and 31%, respectively, for BRCA1 and 27% and 6%, respectively, for BRCA2 mutation carriers. [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/","og_site_name":"JMG Contact blog","article_published_time":"2013-11-27T20:23:03+00:00","article_modified_time":"2026-02-25T19:56:18+00:00","author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations (Contributed by Dr Matti A Rookus)","datePublished":"2013-11-27T20:23:03+00:00","dateModified":"2026-02-25T19:56:18+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/"},"wordCount":130,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/","url":"https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/","name":"Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations (Contributed by Dr Matti A Rookus) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"datePublished":"2013-11-27T20:23:03+00:00","dateModified":"2026-02-25T19:56:18+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2013\/11\/27\/breast-and-ovarian-cancer-risks-in-a-large-series-of-clinically-ascertained-families-with-a-high-proportion-of-brca1-and-brca2-dutch-founder-mutations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations (Contributed by Dr Matti A Rookus)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=600"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/600\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=600"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}